Irrimax Receives Strategic Funding from Decathlon Capital

Sep 11, 2018 8:00 AM

ATLANTA, GA, Sept. 11, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Irrimax Corporation has received significant investment funding from Decathlon Capital Partners to support ongoing development of the company’s medical technology and expand opportunities for its use.

Irrimax invented and developed Irrisept®, an FDA-cleared medical device containing low concentration chlorhexidine gluconate (CHG 0.05%) for irrigation. This proprietary technology is designed to loosen and remove debris without harming underlying tissue during application. Irrisept helps prevent infections, focusing on Hospital Acquired Infections (HAIs) and, ultimately, improves patient outcomes and reduces healthcare costs.  Irrisept has passed required safety testing for cytotoxicity, skin irritation and immune allergic response. This new funding through Decathlon will support ongoing testing as part of Irrisept’s holistic clinical program with the goal of becoming Standard of Care for irrigation.

 “Irrimax actively invests in research designed to support our existing technology and to identify new methods to help prevent infections,” said Irrimax CEO Mark Alvarez. “We are excited to partner with Decathlon. They have provided important funding to advance clinical trial initiatives and add resources needed to expand sales in North America and internationally, exponentially increasing the Company’s value.”

 “Cost-effective medical treatment is one of the key socio-economic issues of our time,” said Decathlon’s John Borchers. “Irrimax is in a unique position as their Irrisept product is on the cutting edge of new technology, and the use of low concentration CHG for irrigation. We are pleased to make this investment in their vision.”

 About Irrimax Corporation

Irrimax Corporation is focused on preventing infections, reducing healthcare costs, improving patient outcomes and driving innovation.  Irrimax has attracted experts in the fields of product development, clinical research, manufacturing and commercialization of medical technologies. Our management team is committed to leading the organization with the highest standards of integrity and accountability.  Learn more at